Skip to main content

Table 5 Effect of cumulative rituximab dose on outcomes

From: Rituximab-containing reduced-intensity conditioning improves progression-free survival following allogeneic transplantation in B cell non-Hodgkin lymphoma

  Number Relative risk 95%CI
lower limit
95%CI
upper limit
p value Overall p value
Chronic GVHD       
Rituximab dose (mg/m2)       
 <1000 208 1     0.03
 1000–1999 110 0.64 0.46 0.90 0.01  
 2000–3375 46 0.92 0.62 1.36 0.67  
Non-relapse mortality       
Rituximab dose (mg/m2)       
 <1000 208 1     0.06
 1000–1999 109 0.90 0.54 1.51 0.70  
 2000–3375 45 0.18 0.04 0.75 0.02  
Progression/relapse       
Rituximab dose (mg/m2)       
 <1000 208 1     0.90
 1000–1999 109 1.01 0.63 1.61 0.97  
 2000–3375 45 0.85 0.40 1.78 0.66  
PFS       
Rituximab dose (mg/m2)       
 <1000 208 1     0.21
 1000–1999 109 0.99 0.70 1.39 0.94  
 2000–3375 45 0.56 0.30 1.07 0.08  
Mortality       
Rituximab dose (mg/m2)       
 <1000 214 1     0.052
 1000–1999 113 1.10 0.76 1.59 0.63  
 2000–3375 47 0.43 0.21 0.90 0.02  
  1. Abbreviations: GVHD graft-versus-host disease